The additive beneficial effect of UW solution and urokinase on experimental microvascular free-flap survival.
Pharmacologic manipulation of free flaps to enhance tolerance to ischemia has become a subject of great interest in the research literature. In an effort to improve survival, perfusion washout of experimental free flaps was performed following an episode of primary ischemia. The perfusates utilized were lactated Ringer's solution (LR), University of Wisconsin solution (UW), a high-molecular-weight medium used in organ preservation, and urokinase, a thrombolytic agent. Seventy-five rats were used in this study and divided into groups of 5 each. A 3 x 6-cm abdominal free flap based on the superficial inferior epigastric vessels was raised in each rat. The free flaps were subjected to either 12 or 18 hr of primary ischemia. Following the period of ischemia, perfusion washout was performed with either LR, UW solution, or urokinase at increasing concentrations alone or in combination with UW solution. Urokinase was first evaluated as a perfusate alone at increasing concentrations. In the 12-hr ischemia group, free-flap survival was shown to increase from 0 percent in the LR-perfused flaps to 20 percent, 60 percent, and 80 percent in flaps perfused with 12,500, 25,000, and 100,000 U of urokinase, respectively (p < 0.05). A similar increase in survival was demonstrated in the 18-hr ischemia group, where 0 percent, 20 percent, and 40 percent of flaps survived following perfusion with 12,500, 25,000, and 100,000 U of urokinase, respectively (p < 0.05). Urokinase was then perfused along with UW solution to evaluate the combined effect on flap survival.(ABSTRACT TRUNCATED AT 250 WORDS)
Senderoff
D M
DM
Department of General Surgery, Mount Sinai Medical Center, New York, NY.
Zhang
W X
WX
Israeli
D
D
Mussat
F
F
Urken
M L
ML
Weinberg
H
H
D000241:Adenosine; D000493:Allopurinol; D000818:Animals; D004338:Drug Combinations; D005978:Glutathione; D006085:Graft Survival / Q000187:drug effects* / Q000502:physiology; D007328:Insulin; D007552:Isotonic Solutions / Q000627:therapeutic use; D019188:Organ Preservation Solutions; D010477:Perfusion; D011887:Raffinose; D051381:Rats; D017207:Rats, Sprague-Dawley; D015427:Reperfusion Injury / Q000517:prevention & control*; D000077331:Ringer's Solution; D012996:Solutions / Q000627:therapeutic use*; D013524:Surgical Flaps / Q000379:methods* / Q000502:physiology; D013997:Time Factors; D014021:Tissue Preservation; D014568:Urokinase-Type Plasminogen Activator / Q000627:therapeutic use*
D004338:Drug Combinations; D007328:Insulin; D007552:Isotonic Solutions; D019188:Organ Preservation Solutions; D012996:Solutions; C055206:University of Wisconsin-lactobionate solution; D000493:Allopurinol; D000077331:Ringer's Solution; D014568:Urokinase-Type Plasminogen Activator; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose